Taking into consideration that CAR T cells recognize tumor surface antigens but not secreted or intracellular ones, Liu et al. developed AFP CAR T cells capable of selective binding to the AFP158–166 peptide which is presented by HLA-A02:01 on the surface of tumor cells in vivo [107]. Here, AFP is linked to neoplasm.